Status:

COMPLETED

Plasma Levels of MK0633 in Children Ages 6-12 (0633-023)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Asthma

Eligibility:

All Genders

6-11 years

Phase:

PHASE1

Brief Summary

To evaluate the safety, tolerability and plasma levels of single oral doses of MK0633 in pediatric asthma patients ages 6 to less than 12 years.

Eligibility Criteria

Inclusion

  • Patient has mild to moderate asthma
  • Patient is able to swallow pills
  • Patient is able to have have blood draws

Exclusion

  • Patient has required a visit to the hospital or emergency room due to an asthmatic event in the last 3 months
  • Patient has an upper respiratory tract infection (URI)
  • Patient has a history of stroke
  • Patient consumes more than 4 caffeinated beverages per day

Key Trial Info

Start Date :

August 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2009

Estimated Enrollment :

22 Patients enrolled

Trial Details

Trial ID

NCT00751413

Start Date

August 1 2008

End Date

January 1 2009

Last Update

June 1 2015

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Plasma Levels of MK0633 in Children Ages 6-12 (0633-023) | DecenTrialz